Navigation Links
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2013 Financial Results
Date:7/25/2013

JERSEY CITY, N.J., July 25, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) (the "Company" or "Optimer") today announced it will report second quarter 2013 financial results after the NASDAQ Global Market closes on Thursday, August 1. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results and highlights for the second quarter and provide a corporate update.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

The conference call may be accessed by dialing (877) 280-7280 for domestic callers and +1 (678) 825-8232 for international callers. Please specify to the operator that you would like to join "Optimer's Financial Results Call."  The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com, where it will be archived for 30 days following the call.

About Optimer Pharmaceuticals
We are a global biopharmaceutical company currently focused on commercializing our antibiotic product DIFICID® (fidaxomicin) tablets in the United States and Canada, and developing other fidaxomicin products in the United States and worldwide, both by ourselves and with our partners and licensees. DIFICID, a macrolide antibacterial drug, was approved by the U.S. Food and Drug Administration on May 27, 2011, for the treatment of Clostridium difficile-associated diarrhea, or CDAD, in adults 18 years of age and older. Fidaxomicin has also received marketing authorization in other jurisdictions, including the European Union, where it is marketed under the trade name DIFICLIR™ by our licensee, Astellas Pharma Europe. CDAD is the most common symptom of Clostridium difficile infection, or CDI. Additional information can be found at http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-964-3418

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
3. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
4. Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
5. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2012 Financial Results
6. Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
7. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
8. Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
9. Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results
10. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
11. Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016   Click here ... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent ... a definitive agreement to acquire Valley Campus Pharmacy, ... ("TNH"), a leading specialty pharmacy that provides individualized ... California . In 2015, TNH generated approximately ...
(Date:4/28/2016)... April 28, 2016  The blood testing market in ... according to Kalorama Information and The Freedonia Group in ... nucleic acid testing.  The healthcare research firm said that ... developing blood collection stations and in improving testing at ... Information,s report, Blood Testing Market in China ...
(Date:4/28/2016)... 28, 2016   Acsis , a leading provider ... IT market research and advisory firm IDC has named ... MarketScape: Worldwide Pharmaceutical Track and Trace Software 2016 Vendor ... an assessment of the capabilities and business strategies of ... market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free Certification Program ... to announce the launch of the GFCP Scoop in response to ... purpose of the GFCP Scoop site is to keep the gluten-free ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the ... Cosmetic dentistry is a fast-growing field as more patients are discovering the many different ... more about the options currently available to them and which ones might work for ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Reltok Nasal Products ... products for the head and neck/ear, nose and throat specialty, has added the KOTLER ... The KOTLER NASAL AIRWAY™ is a newly patented safety device secured by nasal ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, ... round of funding led by Eastside Partners, with participation from existing investor Martin ... customer base and accelerate its technology and product roadmap. , “Jvion ...
(Date:4/29/2016)... ... 2016 , ... Regenerative Medicine Solutions (RMS) scored 94.8124 out of ... them second place for Tampa’s Best Places to Work. They were ranked in the ... great accomplishment for our team,” says RMS Human Resources Manager Irene Miller. “We work ...
Breaking Medicine News(10 mins):